HRMY — Harmony Biosciences Holdings, Inc. stock price, charts and financials

QT82Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
42.74
+0.53+1.26%
OverviewShort InterestFilings
HRMYQT82Harmony Biosciences Holdings, Inc.·NASDAQ
42.74+1.26%
TA
Loading chart...
Screen all →
MLYS+1.60%$27.98VRDN-2.27%$21.93VERA+7.87%$34.27BEAM+6.80%$24.67NAMS+3.54%$21.93CLDX+0.70%$38.98NRIX+1.39%$25.50PHVS+1.20%$38.00
Snapshot
Index-P/E13.88EPS (ttm)3.08Insider Own-Shs Outstand57.89MPerf Week3.99%
Market Cap2.47BForward P/E9.99EPS next Y4.28Insider Trans-0.08%Shs Float50.37MPerf Month10.07%
Enterprise Value1.96BPEG1.75EPS next Q1.11Inst Own-Short Float10.25%Perf Quarter26.56%
Income180.00MP/S2.58EPS this Y28.00%Inst Trans-Short Ratio6.39Perf Half Y53.46%
Sales959.00MP/B2.48EPS next Y8.52%ROA13.20%Short Interest5.16MPerf YTD14.22%
Book/sh17.26P/C3.70EPS next 5Y7.93%ROE20.06%52W High43.49 -1.72%Perf Year32.36%
Cash/sh11.54P/FCF6.77EPS past 3/5Y-3.01% -ROIC14.96%52W Low25.52 67.48%Perf 3Y9.51%
Dividend Est.-EV/EBITDA7.10Sales past 3/5Y25.61% 40.24%Gross Margin75.42%Volatility2.26% 3.04%Perf 5Y12.95%
Dividend TTM-EV/Sales2.04EPS Y/Y TTM22.71%Oper. Margin24.03%ATR (14)1.21Perf 10Y-
Dividend Ex-Date-Quick Ratio3.45Sales Y/Y TTM34.13%Profit Margin18.88%RSI (14)65.61Recom2.54
Dividend Gr. 3/5Y-Current Ratio3.48EPS Q/Q88.24%SMA204.89%Beta0.99Target Price48.50
Payout0.00%Debt/Eq0.28Sales Q/Q30.50%SMA5011.35%Rel Volume0.75Prev Close42.21
Employees293LT Debt/Eq0.18EarningsNov 03SMA20023.81%Avg Volume852.09KPrice42.74
IPO DateAug 19, 2020Option/ShortYes / YesEPS/Sales Surpr.33.84% 4.19%Net Debt/EBITDA-1.43Volume641,382Change1.26%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-26-26InitiatedWolfe ResearchOutperform$60
Aug-05-26ReiteratedDeutsche BankHold$36 → $39
Aug-05-26ReiteratedUBSNeutral$33 → $37
Aug-05-26ReiteratedTruist SecuritiesHold$45 → $34
Aug-04-26ReiteratedOppenheimerOutperform$62 → $70
Jul-31-26ReiteratedMizuhoOutperform$50 → $51
Jun-30-26ReiteratedDeutsche BankHold$31 → $36
Feb-23-26ReiteratedDeutsche BankBuy$31
Feb-19-26ReiteratedMizuho SecuritiesOutperform$46 → $50
Feb-11-26DowngradeUBSBuy → Neutral$43 → $46
Latest News· Times ET
Sep-10-26
Sep-10-2607:01AM
Engaging In Options Activity, Kumar Budur Exercises Options Valued At $262K In Harmony Biosciences HldgsBenzinga
Sep-07-26
Sep-07-2611:59PM
Sonoma Pharmaceuticals (NASDAQ:SNOA) & Harmony Biosciences (NASDAQ:HRMY) Critical Analysisdefenseworld.net
Sep-04-26
Sep-04-2611:30AM
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?Yahoo
Sep-03-26
Sep-03-2608:31AM
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?zacks.com
04:05AM
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congressglobenewswire.com
Sep-01-26
Sep-01-2612:45AM
Canada Pension Plan Investment Board Takes $1.21 Million Position in Harmony Biosciences Holdings, Inc. $HRMYdefenseworld.net
Aug-27-26
Aug-27-2604:05AM
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conferenceglobenewswire.com
Aug-26-26
Aug-26-2605:15AM
This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayBenzinga
Aug-19-26
Aug-19-2611:18PM
Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMYdefenseworld.net
12:14AM
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade)SeekingAlpha
Aug-14-26
Aug-14-2606:05AM
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipelinemarketbeat.com
Aug-12-26
Aug-12-2611:50PM
Harmony Biosciences Holdings, Inc. $HRMY Position Raised by California State Teachers Retirement Systemdefenseworld.net
Aug-07-26
Aug-07-2606:01AM
4 Healthcare Stocks to Watch as Defensive Demand Strengthenszacks.com
Aug-06-26
Aug-06-2607:31AM
4 Stocks Trading Near 52-Week High With More Upside Potentialzacks.com
04:05AM
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposiumglobenewswire.com
Company

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue959868715——————
Cost of Goods Sold Incl. D&A237198157——————
Gross Profit724670558——————
Selling, General and Administrative Excl. Other272272221——————
Research and Development221190146——————
Other Operating Expense
100——————
Operating Income230208191——————
Interest Expense141517——————
Unusual Expense
—————————
Non-Operating Income (Expense)252118——————
Net Income Before Taxes241215192——————
Income Taxes605646——————
Consolidated Net Income180159145——————
Net Income From Continuing Operations180159145——————
Net Income180159145——————
EPS (Recurring)3.132.762.56——————
EPS (Basic, Before Extraordinaries)3.132.762.56——————
EPS (Diluted)3.082.712.51——————
EBITDA276255233——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio13.8813.8113.71——————
Price To Sales Ratio2.582.462.74——————
Gross Margin75.5077.1978.04——————
Operating Margin23.9823.9626.71——————
Net Margin18.7718.3220.28——————
Shares Outstanding585757——————
Market Capitalization2,4792,1331,961——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$45.40$39.89$34.38$28.87$23.36● Close Price0.00M0.36M0.73M1.09M1.45MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Budur KumarCHIEF MEDICAL OFFICERSep 08 '26Sale42.9628,4541,222,25913,115Sep 09
Budur KumarCHIEF MEDICAL OFFICERSep 08 '26Option Exercise30.4922,954699,94236,069Sep 09
Budur KumarCHIEF MEDICAL OFFICERSep 04 '26Sale41.985,500230,91118,615Sep 09
Budur KumarCHIEF MEDICAL OFFICERMay 01 '26Option Exercise0.0018,750032,997May 18
Zaeske Adam H.CHIEF COMMERCIAL OFFICERApr 07 '26Option Exercise0.007,50007,500Apr 09
Kapadia SandipCHIEF FINANCIAL OFFICERJan 26 '26Sale37.153,746139,17124,521Jan 28
Dayno Jeffrey M.PRESIDENT, CEOJan 25 '26Option Exercise0.0013,000013,000Jan 26
Kapadia SandipCHIEF FINANCIAL OFFICERJan 25 '26Option Exercise0.004,72504,725Jan 26
Serafin AndrewCHIEF STRATEGY OFFICERJan 25 '26Option Exercise0.002,60002,600Jan 26
Budur KumarCHIEF MEDICAL OFFICERJan 25 '26Option Exercise0.002,66202,662Jan 26
Serafin AndrewCHIEF STRATEGY OFFICERJan 24 '26Option Exercise0.002,50002,500Jan 26
Budur KumarCHIEF MEDICAL OFFICERJan 24 '26Option Exercise0.002,18802,188Jan 26
Dayno Jeffrey M.PRESIDENT, CEOJan 24 '26Option Exercise0.0010,500010,500Jan 26
Kapadia SandipCHIEF FINANCIAL OFFICERJan 24 '26Option Exercise0.003,81303,813Jan 26
Kapadia SandipCHIEF FINANCIAL OFFICERJan 15 '26Sale35.9220,961752,8330Jan 20
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.